I have developed a strong interest in cancer health disparities—specifically, the genetic and socioeconomic causes for the uneven burden of prostate cancer mortality. African-American men with prostate cancer have a 2.5-fold greater risk of lethal prostate cancer compared to white males. Accordingly, my long-term goal is to promote health equity by way of molecular imaging probe development and applied genomics research. My belief is that the benefits of precision medicine, e.g., the responsible translation of theragnostic agents for prostate cancer, can play a critical role in addressing the disproportionate burden of prostate cancer mortality. Asking provocative questions, enhancing diversity in clinical trial participants, and advancing technological developments at the world-premiere cancer center is the best platform in which to further these efforts.